Diuretic therapy in chronic heart failure: Implications for heart failure nurse specialists

Australian Critical Care

Volumn 16, Issue 2, 2003, Pages 59-69

  Davidson, Patricia ^a,b   Macdonald, Peter ^c   Paull, Glenn ^b   Rees, David ^b   Howes, Laurence ^b   Cockburn, Jill ^d   Brown, Mark ^b  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249018649     PISSN: 10367314     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1036-7314(03)80016-4     Document Type: Article

References (87)

1. McMurray J., and Stewart S. Epidemiology, aetiology and prognosis of heart failure. Heart 83 (2000) 596-602
2. May 7. Krum H., et al. National Heart Foundation of Australia and Cardiac Society of Australia & New Zealand Chronic Heart Failure Clinical Practice Guidelines Writing Panel. Guidelines for management of patients with chronic heart failure in Australia. Medical Journal of Australia 174 9 (2001) 459-466
3. Krum H., Tonkin A., Currie R., Djundjek R., and Johnson C. Frequency, awareness and pharmacological management of chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Medical Journal of Australia 174 9 (2001) 459-466
4. Stewart S., Marley J., and Horowitz J. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with congestive heart failure: a randomised controlled study. The Lancet 354 (1999) 1077-1083
5. Rich M., Beckham V., Wittenberg C., Leaven C., Foreland K., and Carney R. A multidisciplinary intervention prevent the readmission of elderly patients with congestive heart failure. New England Journal of Medicine 333 (1995) 1190-1195
6. Davidson P., Stewart S., Elliott D., Daly J., Sindone A., and Cockburn J. Addressing the burden of heart failure in Australia: the scope for home based interventions. Journal of Cardiovascular Nursing 16 (2001) 56-58
7. Davies M., Gibbs C., and Lip G. Management: diuretics, ACE inhibitors, and nitrates. British Medical Journal 320 (2000) 428-431
8. Piano M., Bondmass M., and Schwertz D. The molecular and cellular pathophysiology of heart failure. Heart & Lung 27 (1998) 3-21
9. June. Albert N. Heart failure: the physiologic basis for current therapeutic options. Critical Care Nurse Supplement (1999) 1-12
10. Francis C., and Chu C. Compensatory and maladaptive responses to cardiac dysfunction. Current Opinion Cardiology 10 (1995) 260-267
11. Katz A. Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle, part II: hypertrophy and dilatation of the failing heart. Journal of Cardiac Failure 4 (1998) 67-81
12. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). American Journal of Cardiology 78 (1996) 902-907
13. Pitt B., Zannad F., Remme W., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 341 (1999) 709-717
14. http://nswh.hcn.net.au
15. Cohn J. Heart Failure. In: Willerson J., and Cohn J. (Eds). Cardiovascular Medicine (1995), Churchill Livingtone, New York
16. Kramer B., Schweda F., and Riegger G. Diuretic treatment and diuretic resistance in heart failure. American Journal of Medicine 106 (1999) 90-96
17. Ellison D. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Annals of Internal Medicine 114 (1991) 886-894
18. Fliser D., Schroter M., Neubeck M., and Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney International 46 (1994) 482-488
19. Knauf H., and Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. Journal of Cardiovascular Pharmacology 29 (1997) 367-372
20. Dormans T., and Gerlag P. Combination of high-dose frusemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. European Heart Journal 17 (1996) 1867-1874
21. http://micromedec.hcn.ner.au
22. Krumholz H., Chen Y., Wang Y., Vaccarino V., Radford M., and Horwitz R. Predictors of readmission among elderly survivors of admission with heart failure. American Heart Journal 139 (2000) 72-77
23. Vasko M., Brown-Cartwright D., Knochel J., et al. Frusemide absorption altered in decompensated congestive heart failure. Annals of Internal Medicine 102 (1985) 314-318
24. Wilson J., Reicheek N., Dunkman W., and Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. American Journal of Medicine 70 (1981) 234-239
25. Dikshit K., Vyden J., Forrester J., et al. Renal and extrarenal effects of frusemide in congestive heart failure after acute myocardial infarction. New England Journal of Medicine 288 (1973) 1087-1090
26. Grady K., Dracup K., Kennedy G., Moser D., Piano M., Stevenson L., and Young J. Team management of patients with heart failure: AHA Scientific Statement. Circulation 102 (2000) 2443-2456
27. Maisel A., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. American Heart Journal 141 (2000) 367-374
28. Lahav M., Regev A., Ra'anani P., and Theodor E. Intermittent administration of frusemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 102 (1992) 725-731
29. National Heart Foundation of Australia/Cardiac Society of Australia & New Zealand Chronic Heart Failure Clinical Practice Guidelines Writing Panel. Guidelines in the Contemporary Management of the Patient with Chronic Heart Failure in Australia (2001), National Heart Foundation of Australia. National Heart Foundation
30. Massie B., and Shah N. Evolving trends in the epidemiologic factors of heart disease: rationale for preventive strategies and comprehensive disease management. American Heart Journal 133 (1997) 703-712
31. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. European Heart Journal 18 (1997) 736-753
32. AHCPR pub. No. 94-0612). Konstam M., Dracup K., et al. Heart Failure: evaluation and care of patients with left ventricular systolic dysfunction: Clinical Practice Guideline No. 11 (1994), Agency for Health Care Policy and Research. Public Health Service, US Department of Health and Human Services, Rockville MD
33. The N.H.F.o.N.Z., C.S.o.A.a.N.Z.a.t.R.N.Z.C.o.G.P.W. New Zealand guidelines for the management of chronic heart failure. New Zealand Journal of Medicine 110 (1997) 99-107
34. Schepkens H., Vanholder R., Billiouw J., and Lameire N. Life threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. American Journal of Medicine 110 (2001) 438-441
35. Friedman E., Shadel M., Halkin H., and Farfel Z. Thiazide-induced hyponatraemia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Annals of Internal Medicine 110 (1989) 24-30
36. Volpe M., Magri P., Rao M., et al. Intrarenal determinants of sodium retention in mild heart failure. Effect of angiotensin-converting enzyme inhibition. Hypertension 30 (1997) 168-176
37. Lee W., and Packer M. Prognostic importance of serum sodium concentration and its modification by commencing enzyme inhibition in patients with severe chronic heart failure. Circulation 73 (1986) 257-267
38. Laragh J. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. New England Journal of Medicine 313 (1985) 1330-1340
39. Dzau V., and Hollenberg N. Renal response to captopril in severe heart failure: role of frusemide in natriuresis and reversal of hyponatraemia. Annals of Internal Medicine 100 (1984) 777-782
40. Riegger G., Liebau G., and Kochsiek K. Antidiuretic hormone in congestive heart failure. American Journal of Medicine 72 (1982) 49-52
41. Anand I., Ferrari R., Kalra G., et al. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure. Circulation 80 (1989) 299-305
42. Anand I., Veal N., Kalra G., et al. Treatment of heart failure with diuretics: body compartments, renal functions and plasma hormones. European Heart Journal 10 (1989) 445-450
43. Johnston G., Hiatt W., Nies A., et al. Factors modifying the early nondiuretic vascular effects of frusemide in man. The possible role of renal prostaglandins. Circulation Research 53 (1983) 630-635
44. Motwani J., Fenwick M., Morton J., and Struthers A. Frusemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 86 (1992) 439-445
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325 (1991) 293-30220
46. Good J., Brady A., Noormohamed F., et al. Effect of intense angiotensin II suppression on the diuretic response to frusemide during chronic ACE inhibition. Circulation 90 (1994) 220-224
47. Waeber B., Brunner H., Burnier M., and Cohn J. Hypertension. In: Willerson J., and Cohn J. (Eds). Cardiovascular Medicine (1995), Churchill Livingtone, New York
48. Dormans T., Van Meyel J., Gelrag P., Tan Y., Russell F., and Smits P. Diuretic efficacy of high dose of furosemide in severe heart failure: bolus injection versus continuous infusion. Journal of the American College of Cardiology 28 (1996) 376-382
49. Rudy D., Voelker J., Greene P., et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Annals of Internal Medicine 115 (1991) 360-366
50. Van Meyel J., Smits P., Dormans T., et al. Continuous infusion of frusemide in the treatment of patients with congestive heart failure and diuretic resistance. Journal of Internal Medicine 235 (1994) 329-334
51. Gerlag P., and Van Meijel J. High-dose frusemide in the treatment of refractory congestive heart failure. Archives of Internal Medicine 148 (1988) 286-291
52. Marangoni E., Oddone A., Surian M., et al. Effect of high-dose frusemide in refractory congestive heart failure. Angiology 41 (1990) 862-868
53. Cockburn J. Patient education and strategies to improve compliance. In: Walls R., and Jenkins C. (Eds). Understanding Asthma (2000), McLelland and Petty, Sydney
54. McCrindle J., Li Kam Wa T., Barron W., and Prescott L. Effect of food on the absorbtion of frusemide and bumetanide in man. British Journal of Clinical Pharmacology 42 (1996) 743-746
55. Sullivan M., and Hawthorne M. Nonpharmacologic interventions in the treatment of heart failure. Journal Cardiovascular Nursing 10 (1996) 47-57
56. Sharpe N., Murphy J., Smith H., and Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. The Lancet i (1988) 255-259
57. Anand I., Kalra G., Harris P., et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 2 (1991) 273-278
58. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection failure and congestive heart failure. New England Journal of Medicine 325 (1991) 293-302
59. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine 3161 (1987) 1429-1435
60. Packer M., Poole-Wilson P., Armstrong P., et al. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. ATLAS Study group. Circulation 100 (1999) 2312-2318
61. Page J., and Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients; an underrecognised public health problem. Archives of Internal Medicine 160 (2000) 777-784
62. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. American Journal of Medicine 110 3A (2001) 33S-42S
63. Fitzgerald G., and Patrono C. The coxibs selective inhibitors of cyclooxygenase-2. New England Journal of Medicine 345 (2001) 433-442
64. McColl G. Treating osteoarthritis: maximising outcomes. Australian Family Physician 27 (1998) 32-35
65. Bombardier C., Laine L., Reicen A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 173 (2000) 274
66. American College of Rheumatology Subcommitee on Osteoarthritis. Arthritis Rheumatology 43 (2000) 1905-1915
67. Kegel L. Advanced practice nurses can refine the management of heart failure. Clinical Nurse Specialist 9 (1995) 76-81
68. In: Stewart S., and Blue L. (Eds). Improving Outcomes in Chronic Heart Failure (2001), BMJ Books
69. Riegel B., Carlson B., and Glaser D. Development and testing of a clinical tool measuring self-management of heart failure. Heart & Lung 29 (2000) 4-12
70. Baas L., Fontana J., and Bhat G. Relationships between self-care resources and the quality of life of persons with heart failure: a comparison of treatment groups. Progress in Cardiovascular Nursing 12 1 (1997) 25-38
71. Happ M., Naylor M., and Roe-Prior P. Factors contributing to rehospitalisation of elderly patients with heart failure. Journal of Cardiovascular Nursing 11 (1997) 75-84
72. Lowe J., Candish P., Henry A., Wlodarcyk J., Heller R., and Fletcher P. Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Medical Journal of Australia 168 (1998) 115-118
73. Cockburn J., Reid A., and Sanson-Fisher R. The process and content of general practice consultations. Medical Journal of Australia 147 (1987) 321-324
74. Rand C., and Wise R. Adherence with Asthma Therapy in the Management of Asthma. Review and Clinical Guidelines (1993), Johns Hopkins School of Medicine, Maryland
75. Ley P., and Llewellyn S. Improving Patients' Understanding, Recall, Satisfaction and Compliance. In: Broome A., and Llewellyn S. (Eds). Health Psychology: Process and applications (1993), Chapman and Hall, Melbourne
76. Nanevicz T., Piette J., Zipkin D., Serlin M., Ennis S., and De Marco T. The feasibility of a telecommunications service in support of outpatient congestive heart failure care in a diverse population. Chronic Heart Failure 6 (2000) 140-145
77. Whishaw M. Urinary incontinence in the elderly: managing for maximum outcomes. Australian Family Physician 27 (1998) 1091-1094
78. Bennett S., Milgrom L., Champion V., and Huster G. Beliefs about medication and dietary compliance in people with heart failure: An instrument development study. Heart & Lung 26 (1997) 273-279
79. In: NYHA - New York Heart Association class - Kossman CE (Ed). Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed (1964), Little Brown, Boston 112
80. http://www.minimental.com
81. Riegel B., Carlson B., and Glaser D. Development and testing of a clinical tool measuring self-management of heart failure. Heart & Lung: Journal of Acute & Critical Care 29 1 (2000) 4-15
82. Jaarsma T., Stromberg A., Martensson J., and Dracup K. Measuring self-care behaviour in heart failure: a new scale ready to use!. Circulation 106 (2002) II 600
83. Stull D., Starling R., Haas G., and Young J. Becoming a patient with heart failure. Heart & Lung 28 (1999) 284-292
84. McMurray J, Cohen-Sola, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockkers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure 220; 3:495-502.
85. Berry C., and McMurray J. Under treatment of heart failure has high cost to patients. British Medical Journal 322 (2001) 731-732
86. Prasun M., Kocheril A., Lass P., Dunlap S., and Piano M. The effects of a diuretic titration protocol in heart failure patients. Circulation 106 (2002) II 321
87. Davidson P., Daly J., Elliott D., and Romanini J. Quality use of medicines (QUM) in critical care: an imperative for best practice. Australian Critical Care 14 3 (2001) 122-126